Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of relapsed CBCC, CC and LPIC lymphoma with FCM chemotherapy alone or in combination with the monoclonal anti CD 20 antibody rituximab followed by anti-CD 20 maintenance or observation only

Next Previous
Trial Profile

Treatment of relapsed CBCC, CC and LPIC lymphoma with FCM chemotherapy alone or in combination with the monoclonal anti CD 20 antibody rituximab followed by anti-CD 20 maintenance or observation only

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide; Fludarabine; Mitoxantrone; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

Most Recent Events

  • 07 May 2021 Biomarkers information updated
  • 27 Jul 2007 The expected completion date for this trial is now 1 Dec 2008.
  • 22 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top